产品
编 号：F754260
分子式：C15H13N5O2
分子量：295.3
分子式：C15H13N5O2
分子量：295.3
产品类型
规格
价格
是否有货
结构图
CAS No: 2642137-96-8
产品详情
生物活性：
Xanthine oxidase-IN-4 (compound 19a) is an orally active and potent xanthine oxidase (XO) inhibitor, with an IC50 of 0.039 μM. Xanthine oxidase-IN-4 exhibits hypouricemic potency in potassium oxonate induced hyperuricemia rats. Xanthine oxidase-IN-4 can be used for hyperuricemia and gout research.
体内研究：
Xanthine oxidase-IN-4 (compound 19a) (SD rats, 10 mg/kg, Intragastrically, once) significantly reduces the serum concentration of uric acid.Animal Model:Sprague-Dawley rats (Six weeks, male, 180-200g, six groups)
Dosage:10 mg/kg
Administration:Intragastrically, once
Result:Significantly reduced the serum concentration of uric acid, with AUC (uric acid, 1-5 h) of 44.3%.
体外研究：
Xanthine oxidase-IN-4 (compound 19a) (1 nM-10 μM, 15 min) exhibits a strong XO inhibitory potency, with an IC50 of 0.039 μM, and Ki of 0.0037 μM.
Xanthine oxidase-IN-4 (compound 19a) is an orally active and potent xanthine oxidase (XO) inhibitor, with an IC50 of 0.039 μM. Xanthine oxidase-IN-4 exhibits hypouricemic potency in potassium oxonate induced hyperuricemia rats. Xanthine oxidase-IN-4 can be used for hyperuricemia and gout research.
体内研究：
Xanthine oxidase-IN-4 (compound 19a) (SD rats, 10 mg/kg, Intragastrically, once) significantly reduces the serum concentration of uric acid.Animal Model:Sprague-Dawley rats (Six weeks, male, 180-200g, six groups)
Dosage:10 mg/kg
Administration:Intragastrically, once
Result:Significantly reduced the serum concentration of uric acid, with AUC (uric acid, 1-5 h) of 44.3%.
体外研究：
Xanthine oxidase-IN-4 (compound 19a) (1 nM-10 μM, 15 min) exhibits a strong XO inhibitory potency, with an IC50 of 0.039 μM, and Ki of 0.0037 μM.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备